Galletti F, Barba G, Nardecchia A, Strazzullo P, Scagliusi P, Pirrelli A, Mancini M
Institute of Internal Medicine and Metabolic Diseases, Medical School, Federico II, University of Naples, Italy.
J Clin Pharmacol. 1994 Sep;34(9):919-23. doi: 10.1002/j.1552-4604.1994.tb04005.x.
The authors studied the antihypertensive effect and tolerability of a new sustained-release formulation of nifedipine 50 mg once a day, in comparison with nifedipine retard 20 mg twice a day in patients with mild or moderate primary arterial hypertension. Both treatments significantly lowered blood pressure with no difference in daily blood pressure profile. At steady state, the two drugs determined comparable plasma levels of nifedipine as measured immediately before the morning dose. After a 12-month treatment, the new formulation of nifedipine still displayed satisfactory blood pressure control in both supine and standing positions, with no change in tolerability throughout the study. In conclusion, this new sustained-release formulation of nifedipine has similar efficacy and tolerability to conventional treatment with nifedipine retard 20 mg twice a day.
作者研究了硝苯地平50毫克每日一次的新型缓释制剂的降压效果和耐受性，并与硝苯地平控释片20毫克每日两次在轻度或中度原发性动脉高血压患者中的效果进行了比较。两种治疗方法均显著降低了血压，每日血压曲线无差异。在稳态时，两种药物测定的硝苯地平血浆水平相当，均在早晨给药前即刻测量。经过12个月的治疗，新型硝苯地平制剂在仰卧位和站立位均仍显示出令人满意的血压控制效果，且在整个研究过程中耐受性无变化。总之，这种新型硝苯地平缓释制剂与硝苯地平控释片20毫克每日两次的传统治疗方法具有相似的疗效和耐受性。
